Skip to main content
Quest Diagnostics

Pharmacogenomics in Mental Health and Addiction

Pharmacogenomics in Mental Health and Addiction

Click here to listen

EPISODE SUMMARY

Today’s podcast discussion will focus on clinical care for patients with mental health disorders. Will discuss and share information regarding:

  • Mental health disorder and substance abuse prevalence
  • The clinical utility of pharmacogenomics in mental health and addiction
  • Mental health disorders and medication nonadherence

The episode will feature Quest Senior Medical Advisor, Dr Jeff Gudin; Medical Liaison Jack Kain, PharmD; and Director, Medical Science Liaison—Neurology and Pharmacogenomics, Raymond Lorenz.

 

Published: July 13, 2021

Presenters: J Gudin, J Kain, RA Lorenz

Related content

Audio Podcast
The CDC Clinical Practice Guideline for Prescribing Opiods for Pain
On-Demand Webinar
Current state of Pharmacogenomics and its future
Publication
Role of Pharmacogenomics in Comprehensive Medication Management: Considerations for Employers
Publication
Early insights from a pharmacogenomic-enriched comprehensive medication management program implementation in an adult employee population

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.